Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.
Copyright © 2025 M&A Critique!. All pages of the Website are subject to our terms and conditions and privacy policy. You must not reproduce, duplicate, copy, sell, resell or exploit any material on the Website for any commercial purposes.We have made a sincere effort to ensure that all photographs used on this website are either freely available in the public domain or used with permission. If you believe your work is being used inappropriately, please let us know and we will address the matter immediately.
[ultimatemember form_id=140]